Annual Report 2024

Department of Diagnostic Pathology

Yasushi Yatabe, Nobuyoshi Hiraoka, Taisuke Mori, Akihiko Yoshida, Masayuki Yoshida, Akiko Maeshima, Hiroshi Yoshida, Taiki Hashimoto, Junpei Kashima, Hirokazu Sugino, Satsuki Kishikawa, Toshihiro Haga, Mai Takeuchi, Naoko Abeto, Shogo Nishino, Yuuto Kaimi, Ayaka Mitsui, Ayumi Sugitani, Keishi Makita, Yumi Asai, Shigeki Sekine, Mana Ideyama, Sachiko Miura, Toshiko Sakaguchi, Kiyono Uchida, Shoichi Harada, Yumiko Sato, Kazumi Yamamoto, Nozomi Handa, Kimii Shiba, Nanako Sugawara, Chika Yabe

Introduction

 The Department of Diagnostic Pathology is responsible for histological and cytological diagnoses and autopsies in the National Cancer Center Hospital. In 2024, the department consisted of 12 staff pathologists, 7 residents, and 15 pathology technologists, including 13 cytotechnologists. We accepted more than 30,000 specimens from the hospital and also provided a total of 260 pathological diagnoses via the pathology consultation.

The Team and What We Do

 The accurate and precise histological and cytological diagnoses play a key role in cancer treatment provided in the hospital. The basis for diagnosis is gross observation and conventional hematoxylin-eosin staining of specimens, however, we also active layer form immunohistochemistry and special stain retrieval. In recent years, the detection of genetic abnormalities and expression of particular molecules have become more important in clinical practice, because several of the alterations have been used to select patients for molecular targeted therapy, treatment using immune checkpoint inhibitors and prediction of clinical outcomes. Although the number of pathological autopsies has remained stable over the past few years, the evaluation of the cause of death, the biological basis of the diseases and therapeutic effects from the autopsy specimens is indispensable to contribute to and improve the quality of medical care in our hospital. This year, we obtained 22,820 biopsy and surgical specimens, 10,699 cytological diagnoses, and 13 autopsies (Table 1). We consider the connection to the clinical departments to be very important; thus we held joint conferences regularly in addition to regular intradepartmental conferences and autopsy reviews.

Table 1. Number of specimens diagnosed in the department (2024)

 We also encourage research work, which includes the studies for improving pathology diagnostics, clarifying biological features of diseases, and providing helpful findings for selecting therapeutic options.

Research Activities

 Hepatobiliary Pancreas

 We reported that the large duct type (LDT) and the small duct type (SDT) of intrahepatic cholangiocarcinoma (iCCA) exhibited distinct clinicopathological characteristics including prognosis based on our analysis of about 200 iCCA cases. We developed a novel immunohistochemical marker capable of distinguishing LDT and SDT with high sensitivity and specificity. This marker could distinguish subtypes of iCCA cases that were difficult to differentiate using existing markers.

 Head and neck and ocular tumors

 We contributed to the development of the second edition of the International Collaboration on Cancer Reporting (ICCR), Carcinoma of the Oral Cavity. We reported that the short-term efficacy of anti-PD-1 antibody monotherapy in recurrent/metastatic head and neck squamous cell carcinoma tended to be better in CPS-positive cases, and that TPS may serve as a predictive marker for identifying patients less likely to benefit from this therapy. We also reported the first case of an orbital perivascular epithelioid cell tumor (PEComa) harboring a ZC3H4::TFE3 fusion and the second reported case involving a PRCC::TFE3 fusion, with discussion of the pathological assessment of their malignant potential. In addition, we reported on the evaluation and diagnostic accuracy of a fine-needle biopsy system developed at our center, applied to a cohort of 41 salivary gland tumors.

 Gynecology

 We have published studies on the following topics: the excellent concordance of molecular classification between resection and biopsy specimens in endometrial carcinoma; the clinicopathological features and HER2 expression of 150 cases of uterine carcinosarcoma in Japan; the characteristics of endometrial lesions in Japanese transgender men; the immune microenvironment and expression of therapeutic targets (TROP2, FRα) in cervical carcinoma; the diagnostic significance of ascitic cytology in gastric-type adenocarcinoma of the uterine cervix; the imaging features of cervical gastric-type adenocarcinoma; genomic analysis of vulvar squamous cell carcinoma in Japan; whole-exome sequencing analysis of vulvar adenocarcinoma of the intestinal type; radiopathological correlation of deep angiomyxoma; the tumor microenvironment of ovarian clear cell carcinoma; and therapeutic targets in ovarian mesonephric-like carcinoma.

 Bone and soft tissue

 We reported the potential diagnostic utility of scattered MUC5AC reactivity in CIC-rearranged sarcoma. We reported 2 cases of inflammatory spindle cell PEComa of the lung with YAP1::TFE3 fusion and discussed their relationship with clear cell stromal tumor. A pediatric soft tissue tumor with MN1::TAF3 fusion was reported. We investigated 20 tumors that would histologically match the recently proposed “calcified chondroid mesenchymal neoplasm”, and discussed the benefits and drawbacks of using this concept in classification.

 Brain tumors

 We developed a genomic profiling test supporting diagnosis and research for gliomas with Division of Brain Tumor Translational Research and Department of Neurosurgery and Neuro-Oncology.

 Breast

 We reported the results of a multi-institutional collaborative study on the significance of tumor-infiltrating lymphocytes in triple-negative breast cancer patients who had not received adjuvant chemotherapy. We also reported the results of a scoring survey on the diagnostic consistency of HER2 in breast cancer, including those with low HER2 expression.

 Respiratory

 We analyzed a novel variant of adenocarcinoma in situ, a preinvasive lesion not previously described in pulmonary adenocarcinoma. Furthermore, we examined lung cancers reported as hepatocellular adenocarcinoma and proposed that hepatocellular differentiation arises from tumor progression or treatment-induced changes, suggesting it may not constitute an independent disease entity in adenocarcinoma.

Education

 We have actively accepted pathology residents and clinical fellows for pathology training and have sent many pathologists to work across the country. With the introduction of the specialist system, we have been operating a training program for board certification as a core institution. At present, six residents and one trainee for the board certification programs are enrolled in the department.

Future Prospects

 Our goal is to accomplish comprehensive pathological diagnosis, which is closely related to clinical practice, with the highest priority on medical safety. We will also train pathologists who are in short supply in Japan and provide training in pathology for tumor diagnosis. It is also important for us to develop research Hospital activities in cooperation with clinical departments and laboratories, and to apply biological abnormalities in tumors to diagnoses.

List of papers published in 2024

Journal

1. Yazaki S, Chiba Y, Kojima Y, Yoshida H, Takamizawa S, Kitadai R, Saito A, Kita S, Yamamoto K, Sumiyoshi-Okuma H, Nishikawa T, Sudo K, Shimoi T, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Yonemori K. Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer. International journal of gynecological pathology, 44:104-111, 2025

2. Mizoguchi C, Nishikawa T, Yoshida H, Yasuda M, Kato T, Hasegawa K, Yonemori K. HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma. Journal of gynecologic oncology, 36:e14, 2025

3. Kojima N, Nishino S, Sasahara Y, Taki T, Imada H, Miyoshi T, Watanabe SI, Ishii G, Yatabe Y, Mori T, Yoshida A. Inflammatory spindle cell PEComa of the lung with YAP1::TFE3 fusion: a report of two cases and a potential relationship with clear cell stromal tumour. Histopathology, 86:365-372, 2025

4. Takigawa W, Yoshida H, Kitamura S, Tokutake C, Kondo M, Fujima M, Shibuki Y, Kobayashi-Kato M, Tanase Y, Uno M, Ishikawa M. Intraoperative peritoneal cytology for cervical gastric-type adenocarcinoma: Cytopathology and clinical impact. Cancer cytopathology, 133:e22915, 2025

5. Kashihara T, Nakamura S, Yamazaki N, Takahashi A, Namikawa K, Ogata D, Nakano E, Okuma K, Kaneda T, Mori T, Ito K, Itami J, Shimada K, Nakagama H, Igaki H. Boron neutron capture therapy for cutaneous angiosarcoma and malignant melanoma: First in-human phase I clinical trial. Radiotherapy and oncology, 202:110607, 2025

6. Sakatani T, Tsuda H, Yoshida M, Honma N, Masuda S, Osako T, Hayashi A, Jara-Lazaro AR, Horii R. Current status and challenges in HER2 IHC assessment: scoring survey results in Japan. Breast cancer research and treatment, 210:27-36, 2025

7. Sakyo A, Ryo E, Nishino S, Kobayashi K, Yoshimoto S, Omura G, Fushimi C, Sakai T, Sakai A, Eguchi K, Takahashi H, Yokoyama K, Honma Y, Mori A, Kato H, Hatano T, Yoshida A, Matsumoto F, Yatabe Y, Mori T. NKX3.1 Helps Distinguish Hyalinizing Clear Cell Carcinoma From Other Clear Cell Salivary Gland Neoplasms. Laboratory investigation; a journal of technical methods and pathology, 105:102205, 2025

8. Sasaki M, Kato D, Yoshida H, Shimizu T, Ogiwara H. Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. Cancer research communications, 5:24-38, 2025

9. Yoshida H, Kikkawa N, Takigawa W, Uno M, Ishikawa M. Unveiling the swirl sign: A radiologic-pathologic correlation in deep angiomyxoma. Annals of diagnostic pathology, 75:152426, 2025

10. Murase Y, Esaki M, Mizui T, Takamoto T, Nara S, Ban D, Hiraoka N, Shimada K. Optimal lymph node dissection area for pancreatic neuroendocrine neoplasms by tumor location, size, and grade. Surgery, 180:109029, 2025

11. Takahashi Y, Yoshida A, Yoshimoto S, Suzuki S, Kishikawa S, Mitsui A, Ryo E, Kojima Y, Yonemori K, Yatabe Y, Mori T. TFE3-rearranged perivascular epithelioid cell tumors of the head and neck with rare fusion partners: clues to the differential diagnosis between benign and malignant tumors. Diagnostic pathology, 20:7, 2025

12. Ohara A, Mori T, Itoyama M, Yokoyama K, Yamamoto S, Kato K, Honma Y. Relationship Between Short-Term Outcomes and PD-L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti-PD-1 Antibody Monotherapy. Cancer reports (Hoboken, N.J.), 8:e70125, 2025

13. Fujii E, Kato MK, Ono H, Yamaguchi M, Higuchi D, Koyama T, Komatsu M, Hamamoto R, Ishikawa M, Kato T, Kohno T, Shiraishi K, Yoshida H. TP53 Mutations and PD-L1 Amplification in Vulvar Adenocarcinoma of the Intestinal Type: Insights From Whole Exome Sequencing of 2 Cases. International journal of gynecological pathology, 44:358-363, 2025

14. Toriyama A, Kishikawa S, Sasaki S, Oh S, Tomita S, Yao T. Squamous cell carcinoma of the bronchus associated with human papillomavirus infection. Respiratory medicine case reports, 53:102162, 2025

15. Nagahashi M, Kumamaru H, Kinukawa N, Iwamoto T, Kawashima M, Kinoshita T, Konishi T, Sagara Y, Sasada S, Saji S, Sanuki N, Tanakura K, Niikura N, Miyashita M, Yoshida M, Ishida T, Taira N. Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression. Breast cancer (Tokyo, Japan), 32:217-226, 2025

16. Sagara Y, Terata K, Sakai T, Takayama S, Kitagawa D, Iwatani T, Tsukioki T, Ogita M, Sanuki N, Yoshida M, Tsuda H, Yamamoto S, Iwata H, Shien T. Design Paper: A Prospective, Multicenter, Single-arm, Phase II Trial of Tailored Axillary Surgery in Patients with Clinically Node-positive Breast Cancer in the Upfront Surgery Setting. JMA journal, 8:264-269, 2025

17. Yoshida K, Yokoi A, Suzuki H, Tamauchi S, Kitagawa M, Inami E, Nakayama J, Mori Y, Okamoto K, Suzuki Y, Yoshida H, Kato T, Kajiyama H, Yamamoto Y. Single-Nucleus RNA Sequencing and Spatial Transcriptomics for Squamous Cell Carcinoma Arising From Ovarian Mature Teratoma. Cancer science, 116:1339-1351, 2025

18. Yorita K, Murayama M, Nakatani K, Tsutsui M, Yoshida H. Multiple Nabothian Cysts and Tunnel Clusters Clinically Mimicking Lobular Endocervical Glandular Hyperplasia: A Case Report. Cureus, 17:e77643, 2025

19. Kawano S, Yoshida H, Kikkawa N, Kobayashi-Kato M, Tanase Y, Uno M, Ishikawa M. Underrecognized diagnostic discordance and delay in endometrial dedifferentiated and undifferentiated carcinoma. The journal of obstetrics and gynaecology research, 51:e16260, 2025

20. Yamanaka T, Nishikawa T, Yoshida H. Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review. Cells, 14:333, 2025

21. Natsume T, Kobayashi-Kato M, Yoshida H, Tanase Y, Uno M, Ishikawa M. Laparoscopic Resection of Central Ovarian Cancer Recurrence in the Pelvis Utilizing a Fluorescent Ureteral Near-Infrared Ray Catheter (NIRC): A Case Report. Cureus, 17:e78970, 2025

22. Nishino S, Mori T, Umezu H, Eguchi K, Hirai T, Yamada R, Ohshima S, Yatabe Y, Yoshimoto S, Kawai A, Motoi T, Yoshida A. Nosologic Reappraisal of the Recently Proposed Calcified Chondroid Mesenchymal Neoplasm Concept in a Series of 20 Cases. Modern pathology, 38:100762, 2025

23. Komiyama S, Okusaka T, Maruki Y, Ohba A, Nagashio Y, Kondo S, Hijioka S, Morizane C, Ueno H, Sukeda A, Mizui T, Takamoto T, Nara S, Ban D, Esaki M, Hiraoka N, Shimada K. Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis. Internal medicine (Tokyo, Japan), 63:891-901, 2024

24. Kojima N, Kubo T, Mori T, Satomi K, Matsushita Y, Iwata S, Yatabe Y, Ichimura K, Kawai A, Ichikawa H, Yoshida A. Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study. Virchows Archiv, 484:71-81, 2024

25. Dacic S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, Berezowska S, Han Y, Chung JH, Beasley MB, Dongmei L, Hwang D, Mino-Kenudson M, Minami Y, Papotti M, Rekhtman N, Roden AC, Thunnissen E, Tsao MS, Yatabe Y, Yoshida A, Wang L, Hartman DJ, Jerome JA, Kadara H, Chou TY, Wistuba II. Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment. Journal of thoracic oncology, 19:273-284, 2024

26. Akamine T, Nakagawa K, Ito K, Watanabe H, Yotsukura M, Yoshida Y, Yatabe Y, Kusumoto M, Watanabe SI. Impact of (18)F-FDG PET on TNM Staging and Prognosis in Thymic Epithelial Tumors. Annals of surgical oncology, 31:192-200, 2024

27. Hirano K, Maruki Y, Yamashige D, Kobayashi O, Shiotsuka M, Morizane C, Imamura T, Hiraoka N, Okusaka T. Two Cases of Disseminated Alveolar Echinococcosis: The Diagnosis, Management, and Differential Considerations for Liver Lesions. Internal medicine (Tokyo, Japan), 63:1247-1252, 2024

28. Odate T, Satomi K, Kubo T, Matsushita Y, Ueno T, Kurose A, Shomori K, Nakai T, Watanabe R, Segawa K, Ohshika S, Miyake N, Kudo S, Shimoi T, Kobayashi E, Komiyama M, Yoshimoto S, Nakatani F, Kawai A, Yatabe Y, Kohsaka S, Ichimura K, Ichikawa H, Yoshida A. Inflammatory Rhabdomyoblastic Tumor: Clinicopathologic and Molecular Analysis of 13 Cases. Modern pathology, 37:100359, 2024

29. Shiraishi K, Takahashi A, Momozawa Y, Daigo Y, Kaneko S, Kawaguchi T, Kunitoh H, Matsumoto S, Horinouchi H, Goto A, Honda T, Shimizu K, Torasawa M, Takayanagi D, Saito M, Saito A, Ohe Y, Watanabe SI, Goto K, Tsuboi M, Tsuchihara K, Takata S, Aoi T, Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Maeda D, Yamaura T, Matsuda M, Shimada Y, Mizuno T, Sakamoto H, Yoshida T, Goto Y, Yoshida T, Yamaji T, Sonobe M, Toyooka S, Yoneda K, Masago K, Tanaka F, Hara M, Fuse N, Nishizuka SS, Motoi N, Sawada N, Nishida Y, Kumada K, Takeuchi K, Tanno K, Yatabe Y, Sunami K, Hishida T, Miyazaki Y, Ito H, Amemiya M, Totsuka H, Nakayama H, Yokose T, Ishigaki K, Nagashima T, Ohtaki Y, Imai K, Takasawa K, Minamiya Y, Kobayashi K, Okubo K, Wakai K, Shimizu A, Yamamoto M, Iwasaki M, Matsuda K, Inazawa J, Shiraishi Y, Nishikawa H, Murakami Y, Kubo M, Matsuda F, Kamatani Y, Hamamoto R, Matsuo K, Kohno T. Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses. Cancer communications (London, England), 44:287-293, 2024

30. Kitadai R, Nishikawa T, Yoshida H, Mizoguchi C, Yamamoto K, Kato T, Yonemori K. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression. Journal of gynecologic oncology, 35:e11, 2024

31. Yatabe Y. Molecular pathology of non-small cell carcinoma. Histopathology, 84:50-66, 2024

32. Takamori S, Yatabe Y, Osoegawa A, Aokage K, Yoshioka H, Miyoshi T, Mimae T, Endo M, Hattori A, Yotsukura M, Isaka T, Isaka M, Maniwa T, Nakajima R, Watanabe SI. Rare but clinically important salivary gland-type tumor of the lung: A review. Japanese journal of clinical oncology, 54:121-128, 2024

33. Kerr KM, Bubendorf L, Lopez-Rios F, Khalil F, Roy-Chowdhuri S, Joubert P, Hartmann A, Guerini-Rocco E, Yatabe Y, Hofman P, Cooper WA, Dacic S. Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists. Histopathology, 84:429-439, 2024

34. Wada S, Nakano E, Nakajima M, Kishikawa S, Yoshida A, Mori T, Osada A, Ogata D, Namikawa K, Yamazaki N. Congenital dermatofibrosarcoma protuberans on the scalp enlarging and shrinking repeatedly. The Journal of dermatology, 51:e196-e197, 2024

35. Sugawara H, Kikkawa N, Ito K, Watanabe H, Kaku S, Akai H, Abe O, Watanabe SI, Yatabe Y, Kusumoto M. Is 18F-fluorodeoxyglucose PET recommended for small lung nodules? CT findings of 18F-fluorodeoxyglucose non-avid lung cancer. The British journal of radiology, 97:462-468, 2024

36. Kaimi Y, Takahashi Y, Taniguchi H, Ochi T, Makino H, Makita S, Iwaki N, Fukuhara S, Munakata W, Ogawa C, Izutsu K, Maeshima AM. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy. Virchows Archiv, 484:465-473, 2024

37. Mochizuki A, Shiraishi K, Honda T, Higashiyama RI, Sunami K, Matsuda M, Shimada Y, Miyazaki Y, Yoshida Y, Watanabe SI, Yatabe Y, Hamamoto R, Kohno T. Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis. Journal of thoracic oncology, 19:984-994, 2024

38. Mori H, Mitsuhashi T, Yatabe Y, Kato J, Tsujikawa H, Matsushita H. Blastic transformation of follicular lymphoma. EJHaem, 5:269-270, 2024

39. Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, Tsuda H, Yamaguchi R, Toyama T, Yamauchi C, Toi M, Yamamoto Y. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan), 31:335-339, 2024

40. Takasawa K, Asada K, Kaneko S, Shiraishi K, Machino H, Takahashi S, Shinkai N, Kouno N, Kobayashi K, Komatsu M, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Kohno T, Hamamoto R. Advances in cancer DNA methylation analysis with methPLIER: use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability. Experimental & molecular medicine, 56:646-655, 2024

41. Kato MK, Fujii E, Asami Y, Momozawa Y, Hiranuma K, Komatsu M, Hamamoto R, Ebata T, Matsumoto K, Ishikawa M, Kohno T, Kato T, Yoshida H, Shiraishi K. Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer. Cancer science, 115:1646-1655, 2024

42. Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Maruyama T, Kuwabara K, Nishizawa T, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments. Cancer science, 115:1763-1777, 2024

43. Iwamoto M, Mori T, Ryo E, Handa S, Nishimura Y, Nagaoka M, Shimoda M. Low-grade carcinoma with acinic cell carcinoma-like features of the parotid gland with CRTC3::IQGAP1 fusion. Pathology international, 74:295-297, 2024

44. Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clément G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, André F, Kok M, Linn SC, Goetz MP, Michiels S. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. JAMA, 331:1135-1144, 2024

45. Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S. The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan), 31:340-346, 2024

46. Miyakoshi J, Yoshida T, Kashima J, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Shiraishi K, Kohno T, Yamamoto N, Yatabe Y, Suzuki T, Ohe Y. Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression. Lung cancer (Amsterdam, Netherlands), 191:107788, 2024

47. Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. ESMO open, 9:102981, 2024

48. Uehara T, Matsuzaki J, Yoshida H, Ogawa Y, Miura J, Fujimiya H, Yamamoto Y, Kawauchi J, Takizawa S, Yonemori K, Sakamoto H, Kato K, Ishikawa M, Ochiya T. Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer. Japanese journal of clinical oncology, 54:917-925, 2024

49. Morii D, Matsui T, Mori T, Yatabe Y, Morii E. Retinal gliosis with osseous metaplasia in an infant. Pathology international, 74:298-300, 2024

50. Mori Y, Okimoto Y, Sakai H, Kanda Y, Ohata H, Shiokawa D, Suzuki M, Yoshida H, Ueda H, Sekizuka T, Tamura R, Yamawaki K, Ishiguro T, Mateos RN, Shiraishi Y, Yatabe Y, Hamada A, Yoshihara K, Enomoto T, Okamoto K. Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer. Cell reports. Medicine, 5:101532, 2024

51. Umino R, Nara S, Mizui T, Takamoto T, Ban D, Esaki M, Hiraoka N, Shimada K. Impact of Surgical Margin Status on Survival and Recurrence After Pancreaticoduodenectomy for Distal Cholangiocarcinoma: Is Microscopic Residual Tumor (R1) Associated with Higher Rates of Local Recurrence? Annals of surgical oncology, 31:4910-4921, 2024

52. Yano K, Yotsukura M, Watanabe H, Akamine T, Yoshida Y, Nakagawa K, Yatabe Y, Kusumoto M, Watanabe SI. Oncological feasibility of segmentectomy for inner-located lung cancer. JTCVS open, 18:261-275, 2024

53. Torasawa M, Yoshida T, Shiraishi K, Goto N, Ueno T, Ichikawa H, Yagishita S, Kohsaka S, Goto Y, Yatabe Y, Hamada A, Mano H, Ohe Y. Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report. JTO clinical and research reports, 5:100657, 2024

54. Li Y, Adusumilli PS, Chou TY, Kadota K, Mino-Kenudson M, Papotti M, Rekhtman N, Yagi Y, Yatabe Y, Travis WD. Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?". Journal of thoracic oncology, 19:677-697, 2024

55. Chiba Y, Kojima Y, Yazaki S, Yoshida H, Takamizawa S, Kitadai R, Saito A, Okuma HS, Nishikawa T, Shimoi T, Sudo K, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Yonemori K. Trop-2 expression and the tumor immune microenvironment in cervical cancer. Gynecologic oncology, 187:51-57, 2024

56. Ozawa R, Nishikawa T, Yoshida H, Shiraishi K, Shimoi T, Kato T, Yonemori K. Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers. Journal of gynecologic oncology, 35:e103, 2024

57. Fujiwara W, Yotsukura M, Yoshida Y, Nakagawa K, Kashima J, Yatabe Y, Watanabe SI. Clinical and Pathologic Differences between Small-Cell Carcinoma and Large-Cell Neuroendocrine Carcinoma of the Lung. Annals of surgical oncology, 31:5697-5705, 2024

58. Klempner SJ, Cowden ES, Cytryn SL, Fassan M, Kawakami H, Shimada H, Tang LH, Wagner DC, Yatabe Y, Savchenko A, Salcius J, Johng D, Chen J, Montenegro G, Moehler M. PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays. JCO precision oncology, 8:e2400230, 2024

59. Tsumura K, Fujimoto M, Tian Y, Kawahara T, Fujimoto H, Maeshima AM, Nakagawa T, Kume H, Yoshida T, Kanai Y, Arai E. Aberrant cell adhesiveness due to DNA hypermethylation of KLF11 in papillary urothelial carcinomas. Experimental and molecular pathology, 137:104908, 2024

60. Sasaki M, Kato D, Murakami K, Yoshida H, Takase S, Otsubo T, Ogiwara H. Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers. Nature communications, 15:4770, 2024

61. Fujii E, Kato MK, Yamaguchi M, Higuchi D, Koyama T, Komatsu M, Hamamoto R, Ishikawa M, Kato T, Kohno T, Shiraishi K, Yoshida H. Genomic profiles of Japanese patients with vulvar squamous cell carcinoma. Scientific reports, 14:13058, 2024

62. Kaneko S, Takasawa K, Asada K, Shiraishi K, Ikawa N, Machino H, Shinkai N, Matsuda M, Masuda M, Adachi S, Takahashi S, Kobayashi K, Kouno N, Bolatkan A, Komatsu M, Yamada M, Miyake M, Watanabe H, Tateishi A, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Saloura V, Kohno T, Hamamoto R. Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations. Molecular cancer, 23:126, 2024

63. Natsume T, Kobayashi-Kato M, Tanase Y, Uno M, Yoshida H, Moritani K, Kanemitsu Y, Ishikawa M. Laparoscopic Posterior Pelvic Exenteration with Radical Vulvectomy for Intestinal-type Vulvar Adenocarcinoma. Gynecology and minimally invasive therapy, 13:126-129, 2024

64. Uchihara M, Tanabe A, Kojima Y, Shimoi T, Maeshima AM, Umamoto K, Shimomura A, Shimizu C, Yamazaki Y, Nakamura E, Matsui Y, Takemura N, Miyazaki H, Sudo K, Yonemori K, Kajio H. Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma. Cancers, 16:2191, 2024

65. Abou-Foul AK, Henson C, Chernock RD, Huang SH, Lydiatt WM, McDowell L, O'Sullivan B, Perez-Ordonez B, Robinson M, Nankivell PC, Ruiz-Bravo E, Chiosea SI, Green TM, Hunter KD, Hwang JS, Koljenovic S, Koppes SA, Larsen SR, Lo AWI, Costes-Martineau V, Mittal N, Mori T, Nagao T, Panayiotides IG, Pinto CAL, Scheckenbach K, Seethala RR, Ulhøi BP, Vingiani A, Zhang Y, Yom SS, Mehanna H. Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations. The Lancet. Oncology, 25:e286-e296, 2024

66. Takahashi Y, Kaimi Y, Taniguchi H, Ochi T, Makino H, Makita S, Iwaki N, Fukuhara S, Munakata W, Izutsu K, Maeshima AM. Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases. Human pathology, 150:78-85, 2024

67. Kawasaki Y, Hijioka S, Nagashio Y, Ohba A, Maruki Y, Takeshita K, Takasaki T, Agarie D, Hagiwara Y, Hara H, Okamoto K, Yamashige D, Kondo S, Morizane C, Ueno H, Mizui T, Takamoto T, Nara S, Ban D, Esaki M, Saito Y, Hiraoka N, Okusaka T. Diagnostic performance of EUS-guided tissue acquisition for solid pancreatic lesions ≦10 mm. Endoscopic ultrasound, 13:115-122, 2024

68. Nishino S, Kojima N, Sugino H, Mori T, Yatabe Y, Yoshida A. MUC5AC immunoreactivity in scattered tumor cells is useful for diagnosing CIC-rearranged sarcoma. Virchows Archiv, 485:359-363, 2024

69. Blechter B, Wang X, Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, Hung RJ, Chen K, Shu XO, Kim YT, Choudhury PP, Williams J, Landi MT, Lin D, Zheng W, Yin Z, Zhou B, Wang J, Seow WJ, Song L, Chang IS, Hu W, Chien LH, Cai Q, Hong YC, Kim HN, Wu YL, Wong MP, Richardson BD, Li S, Zhang T, Breeze C, Wang Z, Bassig BA, Kim JH, Albanes D, Wong JY, Shin MH, Chung LP, Yang Y, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YC, Caporaso NE, Chang J, Man Ho JC, Kubo M, Daigo Y, Song M, Momozawa Y, Kamatani Y, Kobayashi M, Okubo K, Honda T, Hosgood HD, Kunitoh H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Horinouchi H, Tsuboi M, Hamamoto R, Goto K, Ohe Y, Takahashi A, Goto A, Minamiya Y, Hara M, Nishida Y, Takeuchi K, Wakai K, Matsuda K, Murakami Y, Shimizu K, Suzuki H, Saito M, Ohtaki Y, Tanaka K, Wu T, Wei F, Dai H, Machiela MJ, Su J, Kim YH, Oh IJ, Fun Lee VH, Chang GC, Tsai YH, Che KY, Huang MS, Su WC, Chen YM, Seow A, Park JY, Kweon SS, Chen KC, Gao YT, Qian B, Wu C, Lu D, Liu J, Schwartz AG, Houlston R, Spitz MR, Gorlov IP, Wu X, Yang P, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeböller H, Ji BT, Wichmann HE, Christiani DC, Rennert G, Arnold S, Brennan P, McKay J, Field JK, Davies MPA, Shete SS, Le Marchand L, Liu G, Andrew A, Kiemeney LA, Zienolddiny-Narui S, Grankvist K, Johansson M, Cox A, Taylor F, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Jeon HS, Jiang SS, Sung JS, Chen CH, Hsiao CF, Jung YJ, Guo H, Hu Z, Burdett L, Yeager M, Hutchinson A, Hicks B, Liu J, Zhu B, Berndt SI, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Wang WC, Xu J, Guan P, Tan W, Yu CJ, Yang G, Loon Sihoe AD, Chen Y, Choi YY, Kim JS, Yoon HI, Park IK, Xu P, He Q, Wang CL, Hung HH, Vermeulen RCH, Cheng I, Wu J, Lim WY, Tsai FY, Chan JKC, Li J, Chen H, Lin HC, Jin L, Liu J, Sawada N, Yamaji T, Wyatt K, Li SA, Ma H, Zhu M, Wang Z, Cheng S, Li X, Ren Y, Chao A, Iwasaki M, et al. (複数名のため一部抜粋して記載。詳細は掲載先をご参照ください). Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers. medRxiv : the preprint server for health sciences, 2024.06.26.24309127, 2024

70. Itoyama M, Ohara A, Yokoyama K, Yamamoto S, Kato K, Tada Y, Sugitani A, Sugino H, Yatabe Y, Kusumoto M, Nakamura K, Honma Y. An autopsy case of pulmonary tumor thrombotic microangiopathy that developed during chemotherapy for salivary duct carcinoma of the parotid gland. Auris, nasus, larynx, 51:829-833, 2024

71. Kaimi Y, Naka T, Yoshida H, Uno M, Maeshima AM. Histopathology of peritonitis due to infectious mononucleosis with background Chlamydia trachomatis infection: A case report and literature review. Pathology international, 74:611-617, 2024

72. Maeshima AM, Taniguchi H, Takahashi Y, Kaimi Y, Ochi T, Makino H, Makita S, Iwaki N, Fukuhara S, Munakata W, Izutsu K. Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm. Human pathology, 151:105630, 2024

73. Araki M, Mitsuhashi T, Yatabe Y, Arai T, Yokota H, Okita H, Sakurai M, Tsukada N, Kataoka K, Matsushita H. Simple flow cytometry method using a myeloma panel that easily reveals clonal proliferation of mature B-cells. Clinical chemistry and laboratory medicine, 2024

74. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of clinical oncology, 42:3207-3217, 2024

75. Kitadai R, Shimoi T, Yazaki S, Okuma HS, Hoshino M, Ito M, Saito A, Kita S, Kojima Y, Nishikawa T, Sudo K, Noguchi E, Fujiwara Y, Yoshida M, Yonemori K. Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast cancer (Tokyo, Japan), 31:1037-1045, 2024

76. Kishikawa S, Kondo A, Yao T, Saito T. Case report: A mesenchymal chondrosarcoma with alternative HEY1::NCOA2 fusions in the sella turcica. Pathology oncology research : POR, 30:1611730, 2024

77. Kato MK, Fujii E, Yamaguchi M, Higuchi D, Asami Y, Hiranuma K, Komatsu M, Hamamoto R, Matumoto K, Kato T, Kohno T, Ishikawa M, Shiraishi K, Yoshida H. Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma. Gynecologic oncology, 190:139-145, 2024

78. Takeshita K, Hijioka S, Nagashio Y, Hara H, Agarie D, Kawasaki Y, Takasaki T, Yagi S, Hagiwara Y, Okamoto K, Yamashige D, Fukuda S, Kuwada M, Komori Y, Okada M, Maruki Y, Morizane C, Ueno H, Yatabe Y, Okusaka T. Study Protocol for a Prospective Self-Controlled Trial on Success in Meeting Comprehensive Genomic Profiling Analysis Criteria for Specimens Obtained by Endoscopic Ultrasound-Guided Tissue Acquisition Using a 19G Needle from Primary and Metastatic Lesions in Pancreatic Cancer with Metastatic Lesions: The PRIMATE Study. Diseases (Basel, Switzerland), 12:182, 2024

79. Fujiwara Y, Takahashi RU, Saito M, Umakoshi M, Shimada Y, Koyama K, Yatabe Y, Watanabe SI, Koyota S, Minamiya Y, Tahara H, Kono K, Shiraishi K, Kohno T, Goto A, Tsuchiya N. Oncofetal IGF2BP3-mediated control of microRNA structural diversity in the malignancy of early-stage lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 121:e2407016121, 2024

80. Fukuda S, Hijioka S, Nagashio Y, Yamashige D, Agarie D, Hagiwara Y, Okamoto K, Yagi S, Komori Y, Kuwada M, Maruki Y, Morizane C, Ueno H, Hiraoka N, Tsuchiya K, Okusaka T. Utility of Transpapillary Biopsy and Endoscopic Ultrasound-Guided Tissue Acquisition for Comprehensive Genome Profiling of Unresectable Biliary Tract Cancer. Cancers, 16:2819, 2024

81. Asada K, Kaneko S, Takasawa K, Shiraishi K, Shinkai N, Shimada Y, Takahashi S, Machino H, Kobayashi K, Bolatkan A, Komatsu M, Yamada M, Miyake M, Watanabe H, Tateishi A, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Kohno T, Hamamoto R. Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets. Molecular cancer, 23:182, 2024

82. Kudo-Saito C, Matsumura S, Mori T, Honma Y, Yoshimoto S. Prognostic significance of the FSTL1-DIP2A axis in early-stage tongue cancer. American journal of cancer research, 14:3816-3825, 2024

83. Ikeuchi H, Matsuno Y, Kusumoto-Matsuo R, Kojima S, Ueno T, Ikegami M, Kitada R, Sumiyoshi-Okuma H, Kojima Y, Yonemori K, Yatabe Y, Takamochi K, Suzuki K, Yoshioka KI, Mano H, Kohsaka S. Correction: GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway. Oncogene, 43:3079, 2024

84. Ogawa A, Yoshida H, Kawano S, Kikkawa N, Kobayashi-Kato M, Tanase Y, Uno M, Ishikawa M. Ovarian Mesonephric-like Adenocarcinoma: Its Prevalence in a Japanese High-Volume Cancer Center and a Literature Review on Therapeutic Targets. Current oncology (Toronto, Ont.), 31:5107-5120, 2024

85. Nakahara M, Yoshida H, Sakamoto A, Taguchi T, Uno M, Kato T, Ishikawa M. Endometrial cancer and endometrial changes in transgender men: Insights from Japanese individuals on testosterone. The journal of obstetrics and gynaecology research, 50:2019-2028, 2024

86. Miwa M, Kitagawa M, Asami Y, Kobayashi-Kato M, Watanabe T, Ogasawara A, Hiranuma K, Kato H, Saito M, Miyagi Y, Kato T, Yoshida H, Momozawa Y, Kohno T, Shiraishi K, Hasegawa K. Prevalence and outcomes of germline pathogenic variants of homologous recombination repair genes in ovarian cancer. Cancer science, 115:3952-3962, 2024

87. Kirisawa T, Maeshima AM, Okuno T, Matsuda A, Matsui Y. Widespread benign HNF1β-positive solid nests from the urethral diverticulum to the bladder neck: Is it a mesonephric remnant? Pathology international, 74:714-717, 2024

88. Tokura M, Ando MM, Kojima Y, Kitadai R, Yazaki S, Atutubo CMN, Li RK, Perez MZ, Gorospe AE, Madrid MA, Ordinario MVC, Imasa MSB, Sudo K, Shimoi T, Suto A, Kohsaka S, Machida R, Sadachi R, Yoshida M, Yatabe Y, Hata T, Nakamura K, Yonemori K, Shiino S. Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study. Breast cancer : basic and clinical research, 18:11782234241288671, 2024

89. Yamada Y, Nagashima K, Azuma M, Masutani M, Ichikawa H, Iwasa S, Takahashi N, Hirano H, Kanato K, Machida N, Kinoshita T, Hata H, Kawakami H, Takahari D, Boku N, Kurokawa Y, Terashima M, Yoshikawa T, Sekine S, Hiraoka N. Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer. BJC reports, 2:18, 2024

90. Sato C, Sugiyama M, Mori T, Nishino S, Tao K, Ogawa C, Yoshida A. Pediatric Mesenchymal Tumor With MN1::TAF3 Fusion. Genes, chromosomes & cancer, 63:e70009, 2024

91. Kobayashi K, Yoshimoto S, Omura G, Matsumoto Y, Sakai A, Eguchi K, Sakai T, Honma Y, Matsumoto F, Kawazu M, Saito Y, Ryo E, Yoshida A, Yatabe Y, Mori T. An Institutional Experience of Core Needle Biopsy with Cooperative Implementation by Pathologists and Head and Neck Oncologists in Salivary Gland Carcinoma. Head and neck pathology, 18:122, 2024

92. Satake T, Morizane C, Okada M, Nishioka M, Hiraoka N, Nara S, Kakegawa T, Kobayashi M, Koyama K, Esaki M, Okusaka T. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy. Cancer medicine, 13:e70474, 2024

93. Yamamoto G, Tanaka K, Kamata R, Saito H, Yamamori-Morita T, Nakao T, Liu J, Mori S, Yagishita S, Hamada A, Shinno Y, Yoshida T, Horinouchi H, Ohe Y, Watanabe SI, Yatabe Y, Kitai H, Konno S, Kobayashi SS, Ohashi A. WEE1 confers resistance to KRAS(G12C) inhibitors in non-small cell lung cancer. Cancer letters, 611:217414, 2024

94. Kirisawa T, Maeshima A, Kikkawa N, Nakamura E, Shimoi T, Maejima A, Imai T, Hagimoto H, Okuno T, Matsuda A, Shinoda Y, Komiyama M, Fujimoto H, Yonemori K, Matsui Y. Prognostic factors for patients with urachal carcinoma undergoing radical surgery: risk stratification for future prospects of precision oncology. JU Open Plus, 2:e00096, 2024

Book

1. Adenoma and adenocarcinoma of the ciliary body. In: WHO classification of tumours editorial board (ed), WHO classification of tumor 5th ed. Eye tumours